Dideoxynucleoside HIV reverse transcriptase inhibitors and drug-related hepatotoxicity: A case report

被引:4
|
作者
Lapadula G. [1 ]
Izzo I. [1 ]
Costarelli S. [1 ]
Cologni G. [1 ]
Bercich L. [2 ]
Casari S. [1 ]
Gambarotti M. [2 ]
Torti C. [1 ]
机构
[1] Institute of Infectious and Tropical Diseases, University of Brescia, Brescia
[2] Service of Morbid Anatomy, Spedali Civili di Brescia, Brescia
关键词
Ritonavir; Tenofovir; Lactic Acidosis; Stavudine; Nucleoside Reverse Transcriptase Inhibitor;
D O I
10.1186/1752-1947-1-19
中图分类号
学科分类号
摘要
This report regards the case of a 43 year-old HIV-positive woman who developed an episode of serious transaminase elevation during stavudine-including antiretroviral therapy. Diagnostic assessment ruled out hepatitis virus co-infection, alcohol abuse besides other possible causes of liver damage. No signs of lactic acidosis were present. Liver biopsy showed portal inflammatory infiltrate, spotty necrosis, vacuoles of macro- and micro-vesicular steatosis, acidophil and foamy hepatocytes degeneration with organelles clumping, poorly formed Mallory bodies and neutrophil granulocytes attraction (satellitosis). A dramatic improvement in liver function tests occurred when stavudine was discontinued and a new antiretroviral regimen with different nucleoside reverse transcriptase inhibitors was used. The importance of considering hepatotoxicity as an adverse event of HAART including stavudine, even in absence of other signs of mitochondrial toxicity should therefore be underlined. Liver biopsy may provide further important information regarding patients with severe transaminase elevation, for a better understanding of the etiology of liver damage. © 2007 Lapadula et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [1] Drug-related hepatotoxicity
    Mumoli, N
    Cei, M
    Cosimi, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (20): : 2192 - 2192
  • [2] Hepatotoxicity of nucleoside reverse transcriptase inhibitors
    Montessori, V
    Harris, M
    Montaner, JSG
    [J]. SEMINARS IN LIVER DISEASE, 2003, 23 (02) : 167 - 171
  • [3] HIV-1 resistance to dideoxynucleoside reverse transcriptase inhibitors: Genotypic-phenotypic correlations
    Torti, C
    Quiros-Roldan, E
    Monno, L
    Patroni, A
    Saracino, A
    Angarano, G
    Tinelli, C
    Lo Caputo, S
    Pierotti, P
    Mazzotta, F
    Carosi, G
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (05) : 1104 - 1107
  • [4] INHIBITION OF HIV REVERSE-TRANSCRIPTASE BY 2',3'-DIDEOXYNUCLEOSIDE TRIPHOSPHATES
    CHEN, MS
    OSHANA, SC
    [J]. BIOCHEMICAL PHARMACOLOGY, 1987, 36 (24) : 4361 - 4362
  • [5] HIV-1 reverse transcriptase inhibitors: Drug resistance and drug development
    Sluis-Cremer, Nicolas
    Ross, Ted
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (15) : 1809 - 1810
  • [6] Drug-related talaromycosis: A case report
    Lu, Yongsheng
    Shi, Quan
    Yu, Jing
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2020, 34
  • [7] Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors
    Palmon, R
    Koo, BCA
    Shoultz, DA
    Dieterich, DT
    [J]. JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2002, 29 (04) : 340 - 345
  • [8] Current concepts - Drug-related hepatotoxicity
    Navarro, VJ
    Senior, JR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (07): : 731 - 739
  • [9] LATE DISCOVERY OF DRUG-RELATED HEPATOTOXICITY
    LARREY, D
    [J]. GASTROENTEROLOGIE CLINIQUE ET BIOLOGIQUE, 1991, 15 (12): : 875 - 875
  • [10] HIV nucleoside reverse transcriptase inhibitors
    Amblard, Franck
    Patel, Dharmeshkumar
    Michailidis, Eleftherios
    Coats, Steven J.
    Kasthuri, Mahesh
    Biteau, Nicolas
    Tber, Zahira
    Ehteshami, Maryam
    Schinazi, Raymond F.
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 240